Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Losses Down, R&D Expenses Up


RXi Pharmaceuticals this week reported lower first-quarter losses despite increased research and development spending on costs associated with the company's preclinical RNAi-based anti-scarring drug candidate RXI-109.

For the three-month period ended March 31, RXi's net loss was about $3.8 million, or $0.19 per share, compared with a year-ago loss of $3.9 million, or $0.24 per share.

R&D expenses climbed to $2.2 million from $1.9 million in the same period a year earlier, reflecting an increase of $442,000 in studies related to RXI-109, as well as consulting activities.

General and administrative costs rose to $3.1 million from $2.5 million, primarily due to an increase in non-cash share-based compensation.

At the end of the first quarter, RXi had cash, cash equivalents, and short-term investments totaling $11.1 million. With the addition of $10 million raised during an April stock offerings, RXi said it expects its resources will be sufficient to fund operations “through at least the first quarter of 2012.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.